Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(8 sites)

United States

University of Chicago, Chicago, Illinois

Dana Farber Cancer Institute, Boston, Massachusetts

University of North Carolina, Chapel Hill, North Carolina

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

University of Cincinnati, Cincinnati, Ohio

The Ohio State University, Columbus, Ohio

MD Anderson Cancer Center, Houston, Texas

University of Utah, Salt Lake City, Utah